General
Preferred name
ALOGLIPTIN
Synonyms
CHEMBL376359 ()
SYR 322 ()
Alogliptin??SYR-322??benzoate ()
ALOGLIPTIN BENZOATE ()
Alogliptin（SYR-322） ()
Alogliptin£¨SYR-322£©benzoate ()
Alogliptin??SYR-322?? ()
Alogliptin (Benzoate) ()
SYR-322 (free base) ()
Alogliptin (SYR-322) benzoate ()
SYR-322 ()
Alogliptin (as benzoate) ()
Nesina ()
Vipidia ()
Alogliptin (benzoate salt) ()
P&D ID
PD009323
CAS
850649-61-5
1246610-75-2
850649-62-6
Tags
probe
natural product
drug
available
Approved by
FDA
First approval
2013
Drug Status
approved
Drug indication
Type-2 diabetes
Max Phase
Phase 4
Probe info
Probe selectivity
protein-selective
Probe type
P&D approved
calculated probe
Probe sources
High-quality chemical probes
Tool Compound Set
Probe targets
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
ABSORPTION The pharmacokinetics of NESINA was also shown to be similar in healthy subjects and in patients with type 2 diabetes. When single, oral doses up to 800 mg in healthy subjects and type 2 diabetes patients are given, the peak plasma alogliptin concentration (median Tmax) occurred 1 to 2 hours after dosing. Accumulation of aloglipin is minimal. The absolute bioavailability of NESINA is approximately 100%. Food does not affect the absorption of alogliptin. ;
DESCRIPTION Alogliptin is a once-daily, oral dipeptidyl peptidase-4 (DPP-4) inhibitor class anti-diabetic drug. (GtoPdb)
Compound Sets
23
AdooQ Bioactive Compound Library
A13311
A13571
Axon Medchem Screening Library
3310
Cayman Chemical Bioactives
23768
ChEMBL Approved Drugs
CHEMBL227529
CHEMBL376359
ChEMBL Drugs
CHEMBL227529
CHEMBL376359
Drug Repurposing Hub
DrugBank
DB06203
DrugBank Approved Drugs
DB06203
DrugCentral
4340
DrugCentral Approved Drugs
4340
DrugMAP
DM8WI3R
DrugMAP Approved Drugs
DM8WI3R
EU-OPENSCREEN Bioactive Compound Library
EOS101628
Guide to Pharmacology
6319
High-quality chemical probes
PD009323
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL376359
MedChem Express Bioactive Compound Library
HY-A0023
HY-A0023A
NCATS Inxight Approved Drugs
JHC049LO86
Novartis Chemogenetic Library (NIBR MoA Box)
ReFrame library
Selleckchem Bioactive Compound Library
alogliptin
alogliptin-syr-322
TargetMol Bioactive Compound Library
T2401
Tool Compound Set
External IDs
52
Properties
(calculated by RDKit )
Molecular Weight
339.17
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
1
Rotatable Bonds
3
Ring Count
3
Aromatic Ring Count
2
cLogP
0.39
TPSA
97.05
Fraction CSP3
0.39
Chiral centers
1.0
Largest ring
6.0
QED
0.87
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Dipeptidyl peptidase IV
DPP-4
DPP4
DPP-4 inhibitor
Dipeptidyl Peptidase
Ferroptosis
DPP
Pathway
Proteases/Proteasome
Apoptosis
Metabolic Enzyme/Protease
Member status
member
MOA
Dipeptidyl Peptidase IV (CD26
DPP-IV
DP-IV) Inhibitors
dipeptidyl peptidase inhibitor
Indication
diabetes mellitus
Source data